Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company.

Company profile
Ticker
EXEL
Exchange
Website
CEO
Michael M. Morrissey
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Ginkgo Bioworks • Acorda Therapeutics ...
Former names
EXELIXIS INC
SEC CIK
Corporate docs
Subsidiaries
Exelixis Patent Company, LLC • Exelixis Plant Sciences, Inc. • Exelixis U.S., LLC ...
IRS number
43257395
EXEL stock data
Analyst ratings and price targets
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
16 May 23
DFAN14A
Additional proxy materials by non-management
15 May 23
DEFA14A
Additional proxy soliciting materials
15 May 23
DFAN14A
Additional proxy materials by non-management
11 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
DFAN14A
Additional proxy materials by non-management
8 May 23
DFAN14A
Additional proxy materials by non-management
8 May 23
DEFA14A
Additional proxy soliciting materials
8 May 23
8-K
Exelixis Announces Departure of Lance Willsey, M.D. from Board of Directors
8 May 23
Transcripts
EXEL
Earnings call transcript
2023 Q1
9 May 23
EXEL
Earnings call transcript
2022 Q4
7 Feb 23
EXEL
Earnings call transcript
2022 Q3
2 Nov 22
EXEL
Earnings call transcript
2022 Q2
10 Aug 22
EXEL
Earnings call transcript
2022 Q1
11 May 22
EXEL
Earnings call transcript
2021 Q4
18 Feb 22
EXEL
Earnings call transcript
2021 Q3
3 Nov 21
EXEL
Earnings call transcript
2021 Q2
6 Aug 21
EXEL
Earnings call transcript
2021 Q1
7 May 21
EXEL
Earnings call transcript
2020 Q4
11 Feb 21
Latest ownership filings
4
Jeffrey Hessekiel
17 May 23
4
Christopher J. Senner
17 May 23
4
MICHAEL MORRISSEY
17 May 23
4
Dana Aftab
17 May 23
4
Patrick J. Haley
17 May 23
144
Notice of proposed sale of securities
17 May 23
SC 13D/A
Farallon Capital Partners, L.P.
7 Apr 23
4
Jeffrey Hessekiel
5 Apr 23
4
MICHAEL MORRISSEY
5 Apr 23
4
Dana Aftab
5 Apr 23
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jul 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Jan 21 | Jan 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 542.08 mm | 542.08 mm | 542.08 mm | 542.08 mm | 542.08 mm | 542.08 mm |
Cash burn (monthly) | (no burn) | 16.27 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 33.18 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 508.89 mm | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 31.3 | n/a | n/a | n/a | n/a |
Institutional ownership, Q1 2023
92.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 354 |
Opened positions | 39 |
Closed positions | 66 |
Increased positions | 130 |
Reduced positions | 125 |
13F shares | Current |
---|---|
Total value | 5.35 tn |
Total shares | 299.76 mm |
Total puts | 512.50 k |
Total calls | 2.21 mm |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 36.21 mm | $702.92 bn |
Vanguard | 33.12 mm | $642.84 bn |
Farallon Capital Management | 23.47 mm | $455.48 bn |
Farallon Capital Partners | 22.62 mm | $414.64 mm |
Renaissance Technologies | 15.28 mm | $295.49 bn |
STT State Street | 12.96 mm | $251.51 bn |
JPM JPMorgan Chase & Co. | 7.76 mm | $150.71 bn |
T. Rowe Price | 6.01 mm | $116.28 bn |
FMR | 5.97 mm | $115.91 bn |
Meditor | 5.41 mm | $105.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 May 23 | Hessekiel Jeffrey | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 7,027 | 134.78 k | 571,976 |
15 May 23 | Hessekiel Jeffrey | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 4,940 | 94.75 k | 579,003 |
15 May 23 | Haley Patrick J. | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 8,765 | 168.11 k | 316,020 |
15 May 23 | Haley Patrick J. | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 6,274 | 120.34 k | 324,785 |
15 May 23 | Haley Patrick J. | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 3,026 | 58.04 k | 331,059 |
15 May 23 | Senner Christopher J. | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 10,002 | 191.84 k | 571,631 |
15 May 23 | Senner Christopher J. | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 8,444 | 161.96 k | 581,633 |
15 May 23 | Michael Morrissey | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 33,518 | 642.88 k | 608,800 |
15 May 23 | Dana Aftab | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 6,115 | 117.29 k | 410,823 |
15 May 23 | Dana Aftab | Common Stock | Payment of exercise | Dispose F | No | No | 19.18 | 4,373 | 83.87 k | 416,938 |
News
8 Analysts Have This to Say About Exelixis
10 May 23
JMP Securities Reiterates Market Outperform on Exelixis, Maintains $24 Price Target
10 May 23
Piper Sandler Assumes Exelixis at Overweight, Announces Price Target of $28
10 May 23
Exelixis Q1 Adj. EPS $0.16 Beats $0.15 Estimate, Sales $408.79M Miss $424.10M Estimate
9 May 23
Exelixis: Q1 Earnings Insights
9 May 23
Press releases
Farallon Capital Management Comments on Election of All Three of Its Nominees to Exelixis' Board
31 May 23
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in June
30 May 23
Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update
9 May 23
Farallon Capital Management Comments on Successful Campaign for Change at Exelixis
7 May 23
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors
7 May 23